Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz(APLA Health), Joseph J. Eron, Mina C. Hosseinipour, Sue Li(Fred Hutch Cancer Center), Adeola Adeyeye(National Institutes of Health), Myron S. Cohen(University of North Carolina at Chapel Hill), Halima Dawood(Centre for the AIDS Programme of Research in South Africa), Beatriz Grinsztejn(University of Maryland, Baltimore), William Spreen, Marybeth McCauley(Family Health International 360), Ravindre Panchia(Chris Hani Baragwanath Hospital), Craig W. Hendrix(Johns Hopkins University), Albert Liu(San Francisco Department of Public Health), Jeremy Sugarman(Johns Hopkins University), Elizabeth E. Tolley(Family Health International 360), Manya Magnus(Milken Institute), Susan H. Eshleman(Johns Hopkins University), Ryan Kofron(APLA Health), Mark A. Marzinke(Family Health International 360), Alex R. Rinehart, Yinfeng Zhang(Johns Hopkins University), David Burns(Norwegian Womens Public Health Association), Paul Richardson(Johns Hopkins University), Leslie Cottle(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gordon Chau(Fred Hutch Cancer Center), David M. Margolis(University of North Carolina at Chapel Hill)
Cited by 171
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k